UNSPSC 51413912: Vinpoline

This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8CVR3Q9Y6C. European Medicines Agency schedules Vinpoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00071MIG. Vinpoline generally arises in the molecular formula C23H30N2O3.

UNSPSC 51413912 Vinpoline, a Commodity code, covers emergency medical medications and pharmaceutical products that state and local public health and safety agencies procure for emergency response, patient care, and institutional pharmacy operations. State and local governments buying under this code are primarily purchasing specific medications—such as vasopressors, inotropes, antiarrhythmics, and other advanced life support drugs—for fire rescue services, hospital systems, and state health agency networks. Issuing bodies include city purchasing departments, state health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions and authorized wholesalers. Procurements require vendors to meet stringent pharmaceutical compliance standards including FDA approval, current Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) certification, OSHA Hazard Communication Standards for Safety Data Sheets, and accessibility conformance documentation. Delivery timelines are typically compressed—ten calendar days or less from order receipt—with minimum nine-month to one-year expiration dates from acceptance, and contracts often include one-year base terms with options for renewal or extension.

Recent activity spans Florida, Texas, and Minnesota through a mix of spot procurements and cooperative frameworks. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) in April 2026 for advanced life support medications including Labetalol, Epinephrine, Adenosine, and Diltiazem for Tampa Fire Rescue, with an estimated value of $40,000 and a response deadline of April 8, 2026, featuring a 5 percent Small Local Business Enterprise bid discount. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with implementation effective July 1, 2026, and weighted evaluation emphasizing price competitiveness at 75 percent. Vendors must maintain relationships with authorized wholesalers and carry comprehensive insurance including $5 million general liability and $2 million network security and privacy coverage.